Quality Of Life Study For Colorectal Cancer Survivors
Studies quality of life and late side effects in people treated for colorectal cancer.
Plain-language title generated from the registry record
Registry title: Quality Of Life In Colorectal Cancer Survivors
Key facts
- Where
- Ljubljana, SloveniaSee the site
Where in Slovenia
- Institute of Oncology LjubljanaLjubljana, SloveniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Oncology Ljubljana
- Trial code
- NCT07427901
- Record updated
- 23 February 2026
- Original description
The purpose of this study is to identify late adverse effects in colorectal cancer patients that may influence quality of life at 6, 12, and 24 months after oncological treatment. The study aims to assess quality of life in colorectal cancer survivors in relation to psycho-physical-social well-being at different time points and to evaluate the prevalence of late adverse effects and their association with diagnosis and specific oncological treatment.Read full original descriptionShow less
Quality Of Life In Colorectal Cancer Survivors
The purpose of this study is to identify late adverse effects in colorectal cancer patients that may influence quality of life at 6, 12, and 24 months after oncological treatment. The study aims to assess quality of life in colorectal cancer survivors in relation to psycho-physical-social well-being at different time points and to evaluate the prevalence of late adverse effects and their association with diagnosis and specific oncological treatment.
Inclusion: Patients with colorectal cancer (colon or rectal cancer); Age 25 to 65 years; First oncological treatment performed at the Institute of Oncology Ljubljana; Working-capable patients; Ability to complete questionnaires; Ability to provide written informed consent.
Exclusion: Age < 25 years or > 65 years; Patients unable to complete questionnaires; Patients unable to participate in follow-up assessments; Patients who do not provide written informed consent.